Study Shows ResMed's New CPAP Device Increases Patient Compliance

Clinical study confirms new features of S9 Series prolong patients' sleep by up to 30 minutes

OSLO, Norway, September 16, 2010 - ResMed (NYSE: RMD), a leading developer, manufacturer, and distributor of
sleep and respiratory medical equipment today announced the results of a
clinical study confirming that patients' compliance with sleep therapy
increases when using the ResMed's new CPAP device.

    (Logo: photos.prnewswire.com/prnh/20100203/RESMEDLOGO)
    (Logo: www.newscom.com/cgi-bin/prnh/20100203/RESMEDLOGO)

The clinical study of 50 patients suffering from sleep apnoea showed an
improvement of 30 minutes in average daily usage, from a mean of 6 hours 35
minutes on the patient's usual CPAP device, to 7 hours 5 minutes, when using
the new S9 Series.

Sleep apnoea is one of the more common, and yet highly undiagnosed, sleep
disorders. Obstructive sleep apnoea (OSA) is the most common type of sleep
apnoea and is marked by the collapse or obstruction of the airway during
sleep. The most effective treatment is Continuous Positive Airway Pressure
(CPAP) therapy. In this non-invasive treatment, air is pressurised by a small
device and delivered to the airway of the patient through a mask that fits
on/over the nose, or nose and mouth. The pressurised air keeps the upper
airway open and helps the person to get a restful night without interruptions
caused by apnoeas.

A patient's ability to comply with sleep therapy, however, is affected by
potential negative side effects, such as noise from the device, nasal
dryness/congestion and breathing discomfort. To combat these side effects and
increase patients' ability to adhere to the sleep therapy, ResMed has
developed new improved features for its S9 Series including reduced noise,
improved humidification system, and a more comfortable breathing system.

After testing ResMed's new sleep apnoea therapy platform, patients rate
the S9 Series as significantly better than their current device in comfort of
breathing, dryness of nose and mouth, rainout, and noise. In terms of overall
preference, 78% preferred the S9 Series, over their current device.

"For the first time with our new ClimateControl(TM) system, air is
delivered quietly and comfortably at the precise temperature and humidity
that the sleeping patient, provider, and physician have set. S9 Series
provides a significant, patient-perceptible difference in comfort; a true
leap-forward for sleep apnoea therapy," said Michael Farrell, SVP of the
Global Sleep Business Unit at ResMed.

Studies conducted by researchers at Harvard Medical School show that a
lack of sleep negatively affects perception and judgment. In the workplace
sleep deprivation can result in reduced efficiency and productivity, errors,
and accidents. Studies from the Clinical Sciences Research Institute at the
University of Warwick suggest that between 6-8 hours of sleep is the optimal
range.

"We are extremely pleased to see patient tests confirm that the S9 Series
increases patient's compliance and quality of life, making the device a true
revolution in positive airway pressure therapy," added Frank Klein, VP,
European Sleep Business Unit at ResMed.

About the study

The ResMed S9 Compliance Study was conducted as a clinical study of 50
patients at the ResMed Sleep Research Centre in Sydney, Australia. The three
month study comprised three stages: a retrospective study where the patients
used their own device for 28 days, followed by 28 days testing S9 in a
prospective study, and finally returning to the patient's own device for 28
more days in a prospective study.

The purpose of the study was to assess whether compliance is improved by
ResMed's new S9 Series, which features reduced noise, an improved
humidification system and a more comfortable breathing experience. In terms
of average daily usage, compliance on the S9 Series was significantly better
than compliance on the patient's own device, both before and after trialling
an S9 device.

The study is registered in the clinical trial registry
ClinicalTrials.gov, Identifier: NCT01013207

About the S9 Series

The S9 Series is designed to deliver unsurpassed comfort to the patient
by automatically controlling the pressure, temperature and humidity of the
air that the patient breathes. The temperature as well as the humidity is
controlled through input from five different sensors, including sensors close
to the mask, a feature unique to the S9 Series over any of its competition.
Optimal humidification is then achieved automatically. A new enhanced
Easy-Breathe motor also reduces the conducted noise offering the quietest
mask and machine combination available on the market.

About ResMed

ResMed is a leading developer, manufacturer, and distributor of medical
equipment for treating, diagnosing, and managing sleep-disordered breathing
and other respiratory disorders. We are dedicated to developing innovative
products to improve the lives of those who suffer from these conditions and
to increasing awareness among patients and healthcare professionals of the
potentially serious health consequences of untreated sleep-disordered
breathing. For more information on ResMed, visit www.resmed.com.

Henrik Aase, Marketing Communications Director of ResMed - Europe, +47-67-11-88-59, mobile, +47-97-53-91-12, henrik.aase at resmed.com; or for interviews, photos, additional information, Vidar Sie of Burson-Marsteller Oslo, mobile, +47-901-68-829, vidar.sie at bm.com, for ResMed